Medgend Icon







discontinued


Brilinta FDA Approved Drugs

BRILINTA [TicagrelorC23H28F2N6O4S]
RX
-
60mg (oral tablet)
90mg (oral tablet)
Astrazeneca PharmsSep 3, 2015
  • Method of inhibiting platelet aggregation.
  • Reduction of the rate of cardiovascular death, myocardial infarction, and stroke in patients with a history of myocardial infarction.
  • Reduction of the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction.
  • Reduction of the rate of thrombotic events in patients with acute coronary syndrome.
  • Treatment of an arterial thrombotic complication in a patient with coronary artery, cerebrovascular or peripheral vascular disease.
  • Treatment of arterial thrombotic complications selected from the group consisting of unstable angina, thrombotic or embolic stroke, transient ischaemic attacks, peripheral vascular disease and myocardial infarction.
  • Treatment of myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction.
  • Treatment of myocardial infarction in patients with acute coronary syndrome or a history of myocardial infarction.
  • Treatment of myocardial infarction.
  • Treatment of post-myocardial infarction.
  • Treatment of stable and unstable angina.
  • Treatment of stroke in patients with acute coronary syndrome or a history of myocardial infarction.
  • Treatment of stroke.
  • Treatment of thrombotic stroke.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.